timothy sykes logo

Stock News

INmune Bio’s Stock Tanks: Worth Considering?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 6/30/2025, 9:18 am ET 6/30/2025, 9:18 am ET | 5 min 5 min read
INmune Bio’s Stock Tanks: Worth Considering? Thumbnail

In the face of trading down by -62.48%, INmune Bio Inc.’s stock might rise on promising topline results from Alzheimer’s program.

Candlestick Chart

Live Update At 09:18:01 EST: On Monday, June 30, 2025 INmune Bio Inc. stock [NASDAQ: INMB] is trending down by -62.48%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview: Understanding INmune Bio’s Position

The essence of successful trading lies in understanding market dynamics, patience, and timing. Traders often feel the urge to act immediately in volatile markets, but impulsive decisions can lead to significant losses. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This mindset encourages traders to wait for optimal conditions, focusing on the quality of trades over quantity. By following this disciplined approach, traders can better manage risks and increase their chances of success.

When analyzing the financial health and recent performance of INmune Bio, several intriguing aspects come to light. The company’s revenue has plummeted over the years, with a significant decrease noted in its three-year revenue growth rate. Despite broadcasting a 100% gross margin, alarming losses appear evident in its overall profit margins.

Moreover, INmune Bio’s valuation ratios indicate some areas of concern. The price-to-sales ratio looks disproportionately high at 2,474, reflecting market reactions to their limited income stream. Interestingly, while they possess a manageable total debt to equity ratio at 0.01, their balance sheet shows substantial working capital, suggesting short-term liquidity.

During the latest quarter ending Mar 31, 2025, INmune Bio reported a net loss of $9.7M, exacerbated by massive expenses in research and administration. However, the company also demonstrated some positive strides: they’ve managed significant changes in their working capital and saw an infusion from common stock issuances, presenting a mixed picture of their financial adaptability.

Evaluating Recent Market Impact

The announcement regarding the direct share offering has sent ripples across the market, instigating a dive in INMB’s share price. For investors, this move represents both a signal and an opportunity. While diluting equity generally raises concerns about shareholder value, the newfound capital could position INmune Bio to execute necessary operational strategies.

Yet, the company’s recent earnings report reflects persistent struggles with profitability. Some investors might prematurely dismiss INMB based on these results, yet others may see untapped potential if future management decisions capitalize effectively on raised funds.

Historically, the firm’s share price trajectory indicates volatility. Days following Jun 20, 2025, underscored this trend where stock figures first gained ground and subsequently dipped. The undercurrents of such oscillations root from both fiscal data revelations and broader market sentiments.

More Breaking News

Long-Term Outlook: Potential or Pitfall?

Despite the prevailing headwinds, INmune Bio clutches onto its strategic vision. Bridging pharmaceutical innovations with market demands, the company intends to utilize recently raised capital to bolster its product pipeline and extend R&D pursuits. However, continued operational losses could diminish trader trust unless they harvest tangible breakthroughs or collaborations in the sector.

The broader challenge remains for INmune Bio to navigate the landscape of clinical advancements and steer towards trader confidence recovery. Prevailing cash flow issues and recurring losses serve as hurdles, hampering immediate positive turnabouts in stock performance. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mindset is crucial for traders watching INmune Bio, as the journey involves learning from setbacks to refine approaches.

Overall, while the current market pessimism around INMB is palpable, the unfolding chapters in their corporate journey promise fervent watchers the possibility of dramatic turns — which remains the fascination of biotech trading.

Overall, INmune Bio stands at a crossroads. The company faces daunting challenges, yet possesses the potential for an attractive comeback if strategic measures leveraging new capital and innovations set wheels into motion. Reading between the lines, traders bear witness to a daring narrative, marked by both uncertainty and opportunity, one that commands judicious exploration and calculated foresight.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”